These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21142079)
21. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. Zuegg J; Cooper MA Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors. Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294 [TBL] [Abstract][Full Text] [Related]
24. Measurement of diffusion coefficients of parabens and steroids in water and 1-octanol. Seki T; Mochida J; Okamoto M; Hosoya O; Juni K; Morimoto K Chem Pharm Bull (Tokyo); 2003 Jun; 51(6):734-6. PubMed ID: 12808257 [TBL] [Abstract][Full Text] [Related]
25. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer. Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108 [TBL] [Abstract][Full Text] [Related]
26. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Meanwell NA Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149 [TBL] [Abstract][Full Text] [Related]
27. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Baranczewski P; StaĆczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792 [TBL] [Abstract][Full Text] [Related]
28. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). Zhang X; He Y; Liu S; Yu Z; Jiang ZX; Yang Z; Dong Y; Nabinger SC; Wu L; Gunawan AM; Wang L; Chan RJ; Zhang ZY J Med Chem; 2010 Mar; 53(6):2482-93. PubMed ID: 20170098 [TBL] [Abstract][Full Text] [Related]
29. Are there differences between launched drugs, clinical candidates, and commercially available compounds? Ohno K; Nagahara Y; Tsunoyama K; Orita M J Chem Inf Model; 2010 May; 50(5):815-21. PubMed ID: 20394396 [TBL] [Abstract][Full Text] [Related]
30. The physicochemical challenges of designing multiple ligands. Morphy R; Rankovic Z J Med Chem; 2006 Aug; 49(16):4961-70. PubMed ID: 16884308 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, biological activity and molecular dynamics studies of specific protein tyrosine phosphatase 1B inhibitors over SHP-2. Sun SX; Li XB; Liu WB; Ma Y; Wang RL; Cheng XC; Wang SQ; Liu W Int J Mol Sci; 2013 Jun; 14(6):12661-74. PubMed ID: 23774838 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218 [TBL] [Abstract][Full Text] [Related]
33. The effect of descriptor database selection on the physicochemical characterization and prediction of water-air, octanol-air and octanol-water partition constants using the solvation parameter model. Poole CF J Chromatogr A; 2023 Sep; 1706():464213. PubMed ID: 37567000 [TBL] [Abstract][Full Text] [Related]
34. Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 2. Rational Bioavailability Design by Global Sensitivity Analysis To Identify Properties Affecting Bioavailability. Daga PR; Bolger MB; Haworth IS; Clark RD; Martin EJ Mol Pharm; 2018 Mar; 15(3):831-839. PubMed ID: 29337562 [TBL] [Abstract][Full Text] [Related]
35. 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors. Sarver P; Acker M; Bagdanoff JT; Chen Z; Chen YN; Chan H; Firestone B; Fodor M; Fortanet J; Hao H; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu G; Liu S; Liu C; McNeill E; Mohseni M; Sendzik M; Stams T; Spence S; Tamez V; Tichkule R; Towler C; Wang H; Wang P; Williams SL; Yu B; LaMarche MJ J Med Chem; 2019 Feb; 62(4):1793-1802. PubMed ID: 30688459 [TBL] [Abstract][Full Text] [Related]